Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Sequential treatment patterns over time for advanced renal cell carcinoma – Data from the German research platform CARAT.

Goebell, P.J., Grüllich, C., Müller, L., Bögemann, M., Martens, U., von der Heyde, E., Reichert, D., Nusch, A., Schlenska-Lange., A., Wetzel, N., Koska, M., Jänicke, M., Marschner, N., Staehler, M., Grünwald, V., 2022.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: IKCS / Journal: -
CARAT
2023
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K, 2022.

European Journal of Haematology, Volume 108, Issue 2, p. 133-144, 2022.
https://doi.org/10.1111/ejh.13719

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: / Journal: European Journal of Hematology
POSEIDON
2022
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).

Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC, 2021.

International Journal of Cancer, 2021.
https://doi.org/10.1002/ijc.33881

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: / Journal: International Journal of Cancer
LICC
2021
First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.

Müller V, Ruhnke M, Hoffmann O, Grafe A, Tomé O, Fett W, Bruch HR, Sommer-Joos AK, Schneeweiss A, 2021.

The Breast, Volume 60, P70-77, 2021.
DOI:https://doi.org/10.1016/j.breast.2021.08.014

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: / Journal: The Breast
AVANTI
2021
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.

Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Chiabudini M, Fischer von Weikersthal L, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K, 2021

Cancer Medicine, Volume 10, Issue 22, p. 8127-8137, 2021.
http://doi.org/10.1002/cam4.4310

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: / Journal: Cancer Medicine
NEPTUN
2021
Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO.

Zaiss M, Uhlig J, Zahn MO, Decker T, Lehmann HC, Harde J, Hogrefe C, Vannier C, Marschner N, 2021.
Oncol Res Treat. 2021;44(11):613-621. doi: 10.1159/000519000. Epub 2021

Indikation: Breast Cancer, Colorectal Cancer, Kolorektalkarzinom, Mammakarzinom / Veranstaltung: - / Journal: Oncology Research and Treatment
STEFANO
2021
Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Erste Real-World Evidence zu NSCLC Stadium II und III in Deutschland.

Eberhardt W.E.E., Passlick B., Stuschke M., Gröschel A., Christopoulos P., Reck M., Grah C., Groth A., Hipper A.,
Chiabudini M., Fleitz A., Jänicke M., Spring L., Christoph D.C., Bernhardt C., Reiser M., Zahn M.-O., Sebastian M., Griesinger F., Thomas M., CRISP Regiser Gruppe, 2021.

Oncol Res Treat 2021;44(suppl 4):1–329, p. 3.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2021
Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315).

Griesinger F., Sebastian M., Brückl W., Hummel H.-D., Jaeschke B., Kern J., Schumann C., Wesseler C., Jänicke M., Fleitz A., Zacharias S., Hipper A., Groth A., Weichert W., Dörfel S., Petersen V., Schröder J., Wilke J., Eberhardt W.E.E., Thomas M., CRISP Register Gruppe, 2021.

Oncol Res Treat 2021;44(suppl 4):1–329 p. 111

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2021
Die sequentielle Behandlung von Patienten mit metastasiertem Nierenzellkarzinom: Analysen aus der deutschen Registerplattform CARAT.

Goebell P.J., Grüllich C., Müller L., Bögemann M., Martens U., von der Heyde E., Reichert D., Nusch A., Schlenska-Lange A., Wetzel N., Koska M., Jänicke M., Marschner N., Staehler M., Grünwald V., 2021.

Oncol Res Treat 2021;44(suppl 4):1–329 p. 22

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARAT
2021
JADE: Die prospektive, nationale, intersektorale Registerplattform zur Untersuchung von Behandlungsrealität, Wirksamkeit und Erkrankungsverlauf von Patienten mit Hepatozellulärem oder Cholangiozellulärem Karzinom in Deutschland.

Thimme R., Schröder J., Uhlig J., Freiberg-Richter J., Zingerle M., Schlenska-Lange A., Hering-Schubert C., Potthoff K., Bengsch F., Hillebrand L.E., Siebenbach H.U., Jänicke M., Hofmann W.P., Pereira P., Berg T., Galle P., JADE-Studiengruppe, 2021.

Oncol Res Treat 2021;44(suppl 4):1–329 p. 33

Indikation: Leberkrebs, Liver Cancer / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
JADE
2021